Ultragenyx Pharma (RARE) Misses Q3 EPS by 11c

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.64), $0.11 worse than the analyst estimate of ($1.53).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• LG Energy 2q Oper Profit 113.3b Won, Est. 210.66b Won - Bloomberg
• ADNOC Distribution agrees to buy Shell's South Africa unit for $1B